摘要目的 比较多西他赛与顺铂联合方案与紫杉醇联合顺铂方案在食管癌术后辅助化疗的安全性.方法 将郑州人民医院颐和医院82例食管癌术后患者分为两组,研究组(42例)给予多西他赛(75 mg/m2)联合顺铂(60 mg/m2),对照组(40例)给予紫杉醇(135 mg/m2)联合顺铂(60 mg/m2)化疗方案,每3周重复1次,共4～6个周期.结果 研究组化疗后卡氏评分(Karnofsky 1948年的身体功能状态量表)改善率达85.7％,而对照组为55.0％,两组比较差异有统计学意义(P＜0.05),研究组粒细胞减少及消化道反应较对照组明显减少(P＜0.05),而神经毒性、肝脏、肾脏毒性以及心血管毒性两组比较差异无统计学意义.两组均无因化疗毒性所致的给药延迟和(或)剂量调整.结论 食管癌术后辅助化疗中多西他赛联合顺铂生活质量上优于对照组,并且不良反应少,患者更容易耐受,远期疗效有待进一步观察.

abstractsObjective To compare the safety of docetaxel and paclitaxel in the adjuvant chemotherapy of patients with esophageal squamous cell cancer.Methods Eighty-two patients with esophageal squamous cell cancer were randomized divided into two groups.The 42 patients in study group were treated with docetaxel (75 mg/m2)and cisplatin (60 mg/m2)on day 1,every 3 weeks; the 40 cases in control group were treated with paclitaxel (135 mg/m2) and cisplatin (60 mg/m2) on day 1,every 3 weeks.All patients received 4-6 courses of chemotherapy.Results The KPS (Kamofsky Performance Status) improve rate was 85.7％ and 55.0％ in study group and control group,respectively (P ＜ 0.05).The granulocytopenia and gastrointestinal toxicities in study group were much less than those in control group (P ＜ 0.05).There were no significant differences in the neurotoxicity,liver and kidney toxicity or cardiovascular toxicity between the two groups.There were no delayed medication or adjusted dosage induced by chemotherapy toxicity in the two groups.Conclusions Docetaxel plus cisplatin is superior to paclitaxel plus cisplatin in the adjuvant chemotherapy for patients with esophageal squamous cell cancer in the improvement of life quality,and has little side effects,good tolerance.